Heterologous expression of CYP102A5 variant from Bacillus cereus CYPPB-1: Validation of model for predicting drug metabolism of human P450 probe substrates

Applied Microbiology and Biotechnology

Volumn 97, Issue 18, 2013, Pages 8107-8119

  Pendyala, Brahmaiah ^a   Chaganti, Subba Rao ^b   Thadikamala, Sathish ^a   Reddy Shetty, Prakasham ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b UNIVERSITY OF WINDSOR   (Canada)

Author keywords

Bacillus cereus; CYP102A5; Docking studies; Heterologous expression; Homology modeling; Human P450 probe substrates

Indexed keywords

AMINO ACID SEQUENCE; BINDING AFFINITIES; COMPARATIVE SEQUENCE ANALYSIS; CYP102A5; DOCKING STUDIES; HETEROLOGOUS EXPRESSION; HOMOLOGY MODELING; SUBSTRATE BINDING;

AMINO ACIDS; ANILINE; BACILLUS CEREUS; BINDING ENERGY; ESCHERICHIA COLI; FORECASTING; METABOLISM; PHYSIOLOGY; PROBES; PURIFICATION;

SUBSTRATES;

4 NITROPHENOL; ANILINE; BACTERIAL ENZYME; CHLORZOXAZONE; COUMARIN; CYTOCHROME; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 CYP102A5; NIFEDIPINE; PROPRANOLOL; UNCLASSIFIED DRUG;

AMINO ACID; BACTERIUM; DRUG; GENE EXPRESSION; HOMOLOGY; MODEL VALIDATION; PROBE; SUBSTRATE;

AMINO ACID SEQUENCE; ARTICLE; BACILLUS CEREUS; BACTERIAL CELL; BINDING AFFINITY; COMPUTER MODEL; CONTROLLED STUDY; DRUG METABOLISM; ENZYME PURIFICATION; ENZYME SUBSTRATE COMPLEX; ESCHERICHIA COLI; HETEROLOGOUS EXPRESSION; HUMAN; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; SEQUENCE ANALYSIS; VALIDATION PROCESS;

BACILLUS CEREUS; BACILLUS CEREUS ATCC 14579; ESCHERICHIA COLI;

ARYL HYDROCARBON HYDROXYLASES; BACILLUS CEREUS; BACTERIAL PROTEINS; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION; HUMANS; KINETICS; METABOLIC DETOXICATION, DRUG; MOLECULAR DOCKING SIMULATION; SUBSTRATE SPECIFICITY;

EID: 84883557436     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-012-4654-3     Document Type: Article

References (48)

1. Beaudry F, Yves Le Blanc JC, Coutu M, Ramier I, Moreau JP, Brown NK (1999) Metabolite profiling study of propranol in rat using LC/MS/MS analysis. Biomed Chromatogr 13:363-369 (Pubitemid 29381293)
2. Brahmaiah P, Sathish T, Hymavathi M, Reddy KS, Prakasham RS (2010) Sequencing of partial cypD gene for screening of bifunctional cytochrome P450 monooxygenases from Bacillus cereus group. Curr Trends Biotechnol Pharm 4:755-763
3. Chen W, Peter RM, McArdle S, Thunnel KE, Sigle RO, Nelson SD (1996) Baculovirus expression and purification of human and rat cytochrome P450 2E1. Arch Biochem Biophys 335:123-130 (Pubitemid 26382686)
4. Chowdhary PK, Alemseghed M, Haines DC (2007) Cloning, expression and characterization of a fast self-sufficient P450: CYP102A5 from Bacillus cereus. Arch Biochem Biophys 468:32-43 (Pubitemid 350087848)
5. Cryle MJ, Stok JE, De Voss JL (2003) Reactions catalyzed by bacterial cytochromes P450. Aust J Chem 56:749-762
6. Degtyarenko KN, Archakov AI (1993) Molecular evolution of P450 superfamily and P450-containing monooxygenase systems. FEBS Lett 332:1-8 (Pubitemid 23295885)
7. Ekins S, Berbaum J, Harrison RK (2003) Generation and validation of rapid computational filters for CYP2D6 and CYP3A4. Drug Metab Dispos 31:1077-1080 (Pubitemid 37048276)
8. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP (1997) Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput- Aided Mol Des 11:425-445 (Pubitemid 127505895)
9. Fairhead MJ, Giannini S, Gillam EMJ, Gilardi G (2005) Functional characterisation of an engineered multidomain human P450 2E1 by molecular lego. J Biol Inorg Chem 10:842-853 (Pubitemid 41682548)
10. Ghisalba O, Kittelmann M (2007) Preparation of drug metabolites using fungal and bacterial strains. In: Schmid RD, Urlacher V (eds) Modern biooxidations. Enzymes, reactions and applications. Wiley-VCH, Weinheim, pp 211-232
11. Gillam EM, Guo Z, Guengerich FP (1994) Expression of modified human cytochrome P450 2E1 in Escherichia coli, purification, and spectral and catalytic properties. Arch Biochem Biophys 312:59-66 (Pubitemid 24243799)
12. Guengerich FP (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611-650 (Pubitemid 32565712)
13. Guengerich FP (2003) Cytochromes P450, drugs, and diseases. Mol Interv 3:194-204
14. Guengerich FP, Gillam EM, Shimada T (1996) New applications of bacterial systems to problems in toxicology. Crit Rev Toxicol 26:551-583 (Pubitemid 26343226)
15. Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18:2714-2723 (Pubitemid 28059943)
16. Haines DC, Tomchick DR, Machius M, Peterson JA (2001) Pivotal role of water in the mechanism of P450BM-3. Biochemistry 40:13456-13465 (Pubitemid 33130773)
17. Hummel MA, Gannett PM, Aguilar J, Tracy TS (2008) Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone. Arch Biochem Biophys 475:175-183
18. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727-748 (Pubitemid 27170693)
19. Kemp CA, Flanagan JU, van Eldik AJ, Marechal JD, Wolf CR, Roberts GC, Paine MJ, Sutcliffe MJ (2004) Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition. J Med Chem 47:5340-5346 (Pubitemid 39382784)
20. Lewis DF (2004) 57 varieties: the human cytochromes P450. Pharmacogenomics 5:305-318 (Pubitemid 38499969)
21. Lewis DF, Watson E, Lake BG (1998) Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. Mutat Res 410(3):245-270 (Pubitemid 28267162)
22. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM (2003) Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59(5-6):429-442 (Pubitemid 37214951)
23. Lussenburg BM, Babel LC, Vermeulen NP, Commandeur JN (2005) Evaluation of alkoxyresorufins as fluorescent substrates for cytochrome P450 BM3 and site-directed mutants. Anal Biochem 341:148-155 (Pubitemid 40615731)
24. Mansuy D (1994) Cytochromes P-450 and model systems: great diversity of catalyzed reactions. Pure Appl Chem 66(4):737-744
25. Modi S, Primrose WU, Boyle JMB, Gibson CF, Lian LY, Roberts GCK (1995) NMR-studies of substrate-binding to cytochrome-P-450 (BM3): comparisons to cytochrome-P-450 (Cam). Biochemistry 34:8982-8988
26. Nardo GD, Fantuzzi A, Sideri A, Panicco P, Sassone C, Giunta C, Gilardi G (2007) Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem 12:313-323 (Pubitemid 46569275)
27. Narimatsu S, Kobayashi N, Masubuchi Y, Horie T, Kakegawa T, Kobayashi H, Hardwick JP, Gonzalez FJ, Shimada N, Ohmori S, Kitada M, Asaoka K, Kataoka H, Yamamoto S, Satoh T (2000) Species difference in enantioselectivity for the oxidation of propranolol by cytochrome P450 2D enzymes. Chem Biol Interact 127:73-90 (Pubitemid 30618733)
28. Otey CR, Bandara G, Lalonde J, Takahashi K, Arnold FH (2006) Preparation of human metabolites of propanolol using laboratory-evolved bacterial cytochromes P450. Biotechnol Bioeng 93:494-499 (Pubitemid 43232175)
29. Parikh A, Gillam EM, Guengerich FP (1997) Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat Biotechnol 15:784-788 (Pubitemid 27329483)
30. Ravichandran KG, Boddupalli SS, Hasermann CA, Peterson JA, Deisenhofer J (1993) Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. Science 261:731-736 (Pubitemid 23278388)
31. Rea V, Kolkman AJ, Vottero E, Stronks EJ, Ampt KAM, Honing M, Vermeulen NPE, Wijmenga SS, Commandeur JNM (2012) Active site substitution A82W improves the regioselectivity of steroid hydroxylation by cytochrome P450 BM3 mutants as rationalized by spin relaxation nuclear magnetic resonance studies. Biochemistry 51:750-760
32. Rushmore TH, Reider PJ, Slaughter D, Assang C, Shou M (2000) Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites. Metab Eng 2:115-125 (Pubitemid 30416584)
33. Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779-815 (Pubitemid 24007801)
34. Sawayama AM, Chen MM, Kulanthaivel P, Kuo MS, Hemmerle H, Arnold FH (2009) A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds. Chem Eur J 15:11723-11729
35. Semple HA, Xia F (1994) Simplified high-performance liquid chromatographic method for propranolol and five metabolites in liver perfusate, rat serum and dog plasma. J Chromatogr B 655:293-299 (Pubitemid 24169264)
36. Sono M, Roach MP, Coulter ED, Dawson JH (1996) Heme-containing oxygenases. Chem Rev 96(7):2841-2888
37. Streel B, Zimmer C, Sibenaler R, Ceccato A (1998) Simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B 720:119-128 (Pubitemid 29000939)
38. SYBYL (2002) SYBYL version 6.81. Tripos Associates, St. Louis
39. Taylor M, Lamb DC, Cannell R, Dawson M, Kelly SL (1999) Cytochrome P450105D1 (CYP105D1) from Streptomyces griseus: heterologous expression, activity, and activation effects of multiple xenobiotics. Biochem Biophys Res Commun 263:838-842 (Pubitemid 29490714)
40. Tsotsou GE, Cass AE, Gilardi G (2002) High throughput assay for cytochrome P450 BM3 for screening libraries of substrates and combinatorial mutants. Biosens Bioelectron 17:119-131 (Pubitemid 34003618)
41. Urlacher VB, Eiben S (2006) Cytochrome P450 monooxygenases: perspectives for synthetic application. Trends Biotechnol 24:324-330 (Pubitemid 43975576)
42. Vail RB, Homann MJ, Hanna I, Zaks A (2005) Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli. J Ind Microbiol Biotechnol 32:67-74 (Pubitemid 40558570)
43. van de Waterbeemd H, Gifford E (2003) ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2:192-204 (Pubitemid 37361664)
44. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD (2003) Improved protein-ligand docking using gold. Proteins 52:609-623 (Pubitemid 37034158)
45. Vermeulen NPE (2003) Prediction of drug metabolism: the case of cytochrome P450 2D6. Curr Topics Med Chem 3:1227-1239
46. von Weymarn LB, Murphy SE (2001) Coumarin metabolism by rat esophageal microsomes and cytochrome P450 2A3. Chem Res Toxicol 14:1386-1392 (Pubitemid 32983263)
47. Yamazaki H, Nakano M, Gillam EM, Bell LC, Guengerich FP, Shimada T (1996) Requirements for cytochrome b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes. Biochem Pharmacol 52:301-309 (Pubitemid 26233759)
48. Yun CH, Kim KH, Kim DH, Jung HC, Pan JG (2007) The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol 25:289-298 (Pubitemid 46899248)